Conference Coverage

VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy


 

EXPERT ANALYSIS AT SDEF LAS VEGAS DERMATOLOGY SEMINAR

– Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said in a video interview at the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“These are patients who should undergo the type of age-appropriate screening that any patient should have,” including checks for blood pressure and diabetes, said Dr. Gelfand, professor of dermatology and epidemiology at the University of Pennsylvania, Philadelphia.

In terms of preparing for systemic psoriasis therapy, “there are lots of things we can do to lower the risk of having bad outcomes,” including age-appropriate cancer screening such as colonoscopy and mammography, he added. Vaccination is also an important strategy to help reduce the risk of potential side effects related to immunosuppression, he noted.

Dr. Gelfand disclosed relationships with multiple companies including AbbVie, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi, and Valeant.

SDEF and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Birth outcomes unaffected by paternal immunosuppressive therapy
MDedge Rheumatology
Guselkumab achieves highest-ever response rates in psoriasis
MDedge Rheumatology
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
MDedge Rheumatology
Tildrakizumab for psoriasis scores high marks in phase III
MDedge Rheumatology
PsA bone loss measurement: A surrogate for radiographic progression?
MDedge Rheumatology
FDA: Etanercept first biologic approved for pediatric psoriasis
MDedge Rheumatology
What good are biosimilars if patients won’t use them?
MDedge Rheumatology
Optimize anti–TNF-alpha therapy for psoriasis
MDedge Rheumatology
Study offers reassuring data on certolizumab use in pregnancy
MDedge Rheumatology
VIDEO: IL-23 inhibitors on the upswing
MDedge Rheumatology